

## Northwestern University Institutional Biosafety Committee

### Meeting Minutes

Date: 11/19/2025 11:00 AM

Called to Order: 11:02 AM

Adjourned: 1:35 PM

Location: 345 E Superior St, Suite 1522, Chicago, IL 60611

Northwestern University conducts some or all of its IBC meetings via teleconference. A public meeting notice was posted; no comments or attendance requests were received. Attendees of a Northwestern IBC meeting are reminded of confidentiality and conflict of interest expectations. A public meeting notice was posted on the Research Safety website and no public comment was received.

#### IBC Members

Name	Committee Role	Attendance
Mary Hummel	Chair	Present
Greg Smith	Chair	Present
Gregory Beitel	Member	Present
Jennifer Brace	Member	Present
Jacob Class	Member	-
Alexis Demonbreun	Member	Present
Adriana Ferreira	Member	Present
Robert Foreman	Member	Present
Susan Fox	Member	-
Lucy Godley	Member	-
Erica Hartmann	Member	Present
Sydni Hill	Member	Present
Robert Holmgren	Member	Present
Changhwa Hwang	Member	-
Sarah Kopp	Member	Present
Maciej Lesniak	Member	-
Stephen Levin	Member	Present
Liming Li	Member	Present
Emma Liechty	Member	-
Michael McRaven	Member	Present
Jeremy T Ritzert	Member	-
Irina Shepotinovskaya	Member	Present
Suchitra Swaminathan	Member	Present
Clyde Yancy	Member	-
Nicolette Zielinski-Mozny	Member	Present
Robert Birkett	Alternate	Present
Jane Cullen	Alternate	-
Mandy Kozlowski	Alternate	-
Alicia McLuckie	Alternate	-

<b>Name</b>	<b>Committee Role</b>	<b>Attendance</b>
Marina Zelivyanskaya	Alternate	Present
James Zewe	Alternate	Present
Michael Hantak	Administrator	Present
Iwona Spath	Administrator	Present

#### **Registrations for Full-Committee Review**

<b>Research Group</b>	<b>Principal Investigator</b>	<b>Submission Type</b>
Alam Lab	Hasan Alam	Initial Protocol
Amendment for BIO20250079	Luisa Arispe	Amendment
Amendment for BIO20250053	Kelly Bachta	Amendment
Bohnsack Lab	Brenda Bohnsack	Initial Protocol
Dmello Lab	Crismita Dmello	Initial Protocol
Amendment for BIO20220101	Hongxin Dong	Amendment
Ito Lab	Fumiaki Ito	Initial Protocol
McNally Lab	Elizabeth McNally	Initial Protocol
Amendment for BIO20220138	Richard Miller	Amendment
Min Lab	Booki Min	Initial Protocol
Amendment/CR for BIO20230077	Chad Mirkin	Amendment/CR
Muller Lab	William Muller	Initial Protocol
Amendment/CR for BIO20230103	Anna Pfenniger	Amendment/CR
Schwartz Lab	Gregory Schwartz	Initial Protocol
Amendment for BIO20250069	Peter Sporn	Amendment
Zhao (Ming) Lab	Ming Zhao	Initial Protocol

#### **Approval of Previous Meeting Minutes**

Previous Meeting Date: 10/15/25 11:00 AM

Determination: Approve

Comments: A Committee Member made a motion to approve the meeting minutes. The Committee unanimously supported the motion.

## Meeting Minutes

### Review of Alam Lab

#### Initial Protocol

**Principal Investigator:** Hasan Alam

**Submission ID:** BIO20250106

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Amendment for BIO20250079**

### **Amendment**

**Principal Investigator:** Luisa Arispe

**Submission ID:** BIO20250079-AM0001

#### **Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-E-3
- Section III-D-4-b
- Section III-F-8-C-I
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-D-2-a
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8-C-VIII
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Amendment for BIO20250053**

### **Amendment**

**Principal Investigator:** Kelly Bachta

**Submission ID:** BIO20250053-AM0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-D-4-b
- Section III-D-4
- Section III-F-7
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-F-8
- Section III-F-6

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Bohnsack Lab**

### **Initial Protocol**

**Principal Investigator:** Brenda Bohnsack

**Submission ID:** BIO20250109

**Applicable NIH Guidelines:**

- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approve

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Dmello Lab**

### **Initial Protocol**

**Principal Investigator:** Crismita Dmello

**Submission ID:** BIO20250100

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved with minor modifications

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

## **Review of Amendment for BIO20220101**

### **Amendment**

**Principal Investigator:** Hongxin Dong

**Submission ID:** BIO20220101-AM0001

#### **Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-D-4-b
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.



## **Review of Ito Lab**

### **Initial Protocol**

**Principal Investigator:** Fumiaki Ito

**Submission ID:** BIO20250096

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of McNally Lab**

### **Initial Protocol**

**Principal Investigator:** Elizabeth McNally

**Submission ID:** BIO20250103

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-a
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Amendment for BIO20220138**

### **Amendment**

**Principal Investigator:** Richard Miller

**Submission ID:** BIO20220138-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved with minor modifications

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

## Review of Min Lab

### Initial Protocol

**Principal Investigator:** Booki MIn

**Submission ID:** BIO20250108

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-E
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved with minor modifications

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

## **Review of Amendment/CR for BIO20230077**

Amendment/CR

**Principal Investigator:** Chad Mirkin

**Submission ID:** BIO20230077-AMCR0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-F-8-C-I
- Section III-D-4
- Section III-F
- Section III-F-8-C-VI
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Muller Lab**

### **Initial Protocol**

**Principal Investigator:** William Muller

**Submission ID:** BIO20240139

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved with minor modifications

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission with minor modifications.

The Committee unanimously supported the motion.

## **Review of Amendment/CR for BIO20230103**

Amendment/CR

**Principal Investigator:** Anna Pfenniger

**Submission ID:** BIO20230103-AMCR0001

**Applicable NIH Guidelines:**

- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3

**Highest Applicable Containment Level for Proposed Look:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Schwartz Lab**

### **Initial Protocol**

**Principal Investigator:** Gregory Schwartz

**Submission ID:** BIO20250105

**Applicable NIH Guidelines:**

- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.



## **Review of Amendment for BIO20250069**

### **Amendment**

**Principal Investigator:** Peter Sporn

**Submission ID:** BIO20250069-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-E
- Section III-D
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Approved

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to approve this submission.

The Committee unanimously supported the motion.

## **Review of Zhao (Ming) Lab**

### **Initial Protocol**

**Principal Investigator:** Ming Zhao

**Submission ID:** BIO20240056

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F1
- Section III-F-8

**Highest Applicable Containment Level for Proposed Work:** BSL-2

**Determination:** Deferred

**Comments:** The initial submission and any subsequent amendments describe all IBC-reviewed activities relating to work conducted in the above-referenced PI's lab.

Training for the PI and all applicable lab personnel was current at the time the submission was approved.

Research Safety regularly conducts facility inspections of spaces associated with this work year and has determined it is in compliance with applicable institutional and federal policies.

The Primary Reviewer provided a summary of this submission to the Committee which includes a thorough risk assessment as described in NIH Guidelines Section II-A-3.

The Primary Reviewer made a motion to defer this submission.

The Committee unanimously supported the motion.

## **Administratively-Approved Exempt Registrations and Amendments**

### **Amendment/CR for BIO20240035**

Amendment/CR

**Principal Investigator:** Mohamed Abdel-Mohsen

**Submission ID:** BIO20240035-AMCR0001

**Applicable NIH Guidelines:**

- Section III-D-4-b
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-D-3

**Containment Level:** BSL-2+

**Approval Date:** 11/11/2025

### **Amendment/CR for BIO20240024**

Amendment/CR

**Principal Investigator:** Christopher Ahuja

**Submission ID:** BIO20240024-AMCR0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-D-4
- Section III-D-2-a
- Section III-F-1
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 10/13/2025

## **Amendment for BIO20240157**

### **Amendment**

**Principal Investigator:** Irina Balyasnikova

**Submission ID:** BIO20240157-AM0002

#### **Applicable NIH Guidelines:**

- Section III-E-3
- • Section III-E-3-a
- • Section III-D-4
- • Section III-F
- • Section III-E
- • Section III-D-2-a
- • Section III-D-1
- • Section III-F-8-C-VII
- • Section III-D-2
- • Section III-D
- • Section III-D-3

**Containment Level:** BSL-2

**Approval Date:** 11/3/2025

## **Continuing Review for BIO20240047**

### **Continuing Review**

**Principal Investigator:** Daniel Dombeck

**Submission ID:** BIO20240047-CR0001

#### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/12/2025

## **Amendment for BIO20220031**

### **Amendment**

**Principal Investigator:** Francesca Duncan

**Submission ID:** BIO20220031-AM0004

#### **Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-3-d
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/29/2025

### **Continuing Review for BIO20220034**

Continuing Review

**Principal Investigator:** Lillian Eichner

**Submission ID:** BIO20220034-CR0003

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/20/2025

### **Continuing Review for BIO20220131**

Continuing Review

**Principal Investigator:** David Gate

**Submission ID:** BIO20220131-CR0002

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1

**Containment Level:** BSL-2

**Approval Date:** 11/10/2025

### **Continuing Review for BIO20230009**

Continuing Review

**Principal Investigator:** Richard Green

**Submission ID:** BIO20230009-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/20/2025

## **Continuing Review for BIO20220040**

Continuing Review

**Principal Investigator:** Alicia Guemez Gamboa

**Submission ID:** BIO20220040-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/27/2025

## **Amendment/CR for BIO20240163**

Amendment/CR

**Principal Investigator:** CJ Heckman

**Submission ID:** BIO20240163-AMCR0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-1

**Approval Date:** 11/12/2025

## **Amendment for BIO20250033**

### **Amendment**

**Principal Investigator:** Amy Heimberger

**Submission ID:** BIO20250033-AM0001

**Applicable NIH Guidelines:**

- Section III-D-1-a
- Section III-F-2
- Section III-E-3
- Section III-E-3-a
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3-a
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/12/2025

## **Continuing Review for BIO20240102**

### **Continuing Review**

**Principal Investigator:** Pouya Jamshidi

**Submission ID:** BIO20240102-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** BSL-2

**Approval Date:** 11/12/2025

## **Continuing Review for BIO20240112**

Continuing Review

**Principal Investigator:** Ashty Stephen Karim

**Submission ID:** BIO20240112-CR0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-4
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/22/2025

## **Continuing Review for BIO20220044**

Continuing Review

**Principal Investigator:** Jennifer Kearney

**Submission ID:** BIO20220044-CR0002

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/11/2025



## **Amendment for BIO20220042**

### **Amendment**

**Principal Investigator:** John Kessler

**Submission ID:** BIO20220042-AM0003

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/3/2025

## **Continuing Review for BIO20230076**

### **Continuing Review**

**Principal Investigator:** Irum Khan

**Submission ID:** BIO20230076-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4-b
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D
- Section III-D-3
- Section III-D-3-a
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/6/2025

## **Continuing Review for BIO20230070**

### Continuing Review

**Principal Investigator:** Carole LaBonne

**Submission ID:** BIO20230070-CR1

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-1

**Approval Date:** 11/11/2025

## **Continuing Review for BIO20220136**

### Continuing Review

**Principal Investigator:** Laimonis Laimins

**Submission ID:** BIO20220136-CR0002

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/22/2025

## **Amendment for BIO20250087**

### Amendment

**Principal Investigator:** Loretta Li

**Submission ID:** BIO20250087-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-2
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 10/31/2025

## **Continuing Review for BIO20240110**

Continuing Review

**Principal Investigator:** Huiping Liu

**Submission ID:** BIO20240110-CR0001

**Applicable NIH Guidelines:**

**Containment Level:** BSL-2

**Approval Date:** 9/24/2025

## **Amendment/CR for BIO20240142**

Amendment

**Principal Investigator:** Julius Lucks

**Submission ID:** BIO20240142-AMCR0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-F-8-C-V
- Section III-F
- Section III-E
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-2
- Section III-D
- Section III-F-8-C-III
- Section III-F-4
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/5/2025

## **Amendment for BIO20230079**

Amendment

**Principal Investigator:** Joshua Meeks

**Submission ID:** BIO20230079-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- • Section III-D-4
- • Section III-F
- • Section III-E
- • Section III-F-1
- • Section III-D-1
- • Section III-F-8-C-VII
- • Section III-D-2
- • Section III-D
- • Section III-D-3
- • Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/17/2025

## **Amendment for BIO20240092**

### **Amendment**

**Principal Investigator:** Diana Nora Vaz Saleiro

**Submission ID:** BIO20240092-AM0001

#### **Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 11/12/2025

## **Amendment/CR for BIO20240092**

### **Amendment/CR**

**Principal Investigator:** Diana Nora Vaz Saleiro

**Submission ID:** BIO20240092-AMCR0001

#### **Applicable NIH Guidelines:**

- Section III-F-2
- Section III-E-3
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-D
- Section III-D-3
- Section III-F-8-C-VIII
- Section III-F-8

**Containment Level:** BSL-2+

**Approval Date:** 10/20/2025

## **Continuing Review for BIO20230023**

### Continuing Review

**Principal Investigator:** Clara Peek

**Submission ID:** BIO20230023-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-F-8-C-I
- Section III-D-4
- Section III-D-4-c-(1)
- Section III-F
- Section III-F-8-C-II
- Section III-F-1
- Section III-D-1
- Section III-F-8-C-VII
- Section III-D
- Section III-D-3-e

**Containment Level:** BSL-2

**Approval Date:** 10/22/2025

## **Continuing Review for BIO20240041**

### Continuing Review

**Principal Investigator:** Susan Quaggin

**Submission ID:** BIO20240041-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-1
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/13/2025

## **Continuing Review for BIO20240009**

### Continuing Review

**Principal Investigator:** Ishwar Radhakrishnan

**Submission ID:** BIO20240009-CR0002

**Applicable NIH Guidelines:**

- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/10/2025

## **Continuing Review for BIO20230008**

Continuing Review

**Principal Investigator:** Claus-Peter Richter

**Submission ID:** BIO20230008-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-E-3-a
- Section III-F
- Section III-F-8-C-VII

**Containment Level:** BSL-1

**Approval Date:** 9/2/2025

## **Rosenzweig Lab**

Initial Protocol

**Principal Investigator:** Amy Rosenzweig

**Submission ID:** BIO20250064

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-D-6
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D
- Section III-F-8

**Containment Level:** BSL-1

**Approval Date:** 10/16/2025

## **Continuing Review for BIO20230017**

Continuing Review

**Principal Investigator:** Megan Roy-Puckelwartz

**Submission ID:** BIO20230017-CR0002

**Applicable NIH Guidelines:**

**Containment Level:** BSL-1

**Approval Date:** 11/12/2025

## **Continuing Review for BIO20240147**

### Continuing Review

**Principal Investigator:** Iris Titos Vivancos

**Submission ID:** BIO20240147-CR0001

**Applicable NIH Guidelines:**

- Section III-D-4
- Section III-F
- Section III-F-1
- Section III-D-2
- Section III-D

**Containment Level:** N/A

**Approval Date:** 10/31/2025

## **Continuing Review for BIO20240077**

### Continuing Review

**Principal Investigator:** Sergey Troyanovsky

**Submission ID:** BIO20240077-CR0001

**Applicable NIH Guidelines:**

- Section III-F
- Section III-F-1
- Section III-D-2
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/20/2025

## **Amendment for BIO20240080**

### Amendment

**Principal Investigator:** Joshua Wechsler

**Submission ID:** BIO20240080-AM0001

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-F
- Section III-E
- Section III-F-1
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/16/2025

## **Continuing Review for BIO20240095**

Continuing Review

**Principal Investigator:** Yue Yang

**Submission ID:** BIO20240095-CR0001

**Applicable NIH Guidelines:**

- Section III-F-2
- Section III-D-4-b
- Section III-D-4-a
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D-4-c-(2)
- Section III-D-2
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 11/6/2025

## **Continuing Review for BIO20220127**

Continuing Review

**Principal Investigator:** Peng Zhang

**Submission ID:** BIO20220127-CR0002

**Applicable NIH Guidelines:**

- Section III-E-3
- Section III-D-4
- Section III-F
- Section III-E
- Section III-F-1
- Section III-D
- Section III-F-8

**Containment Level:** BSL-2

**Approval Date:** 10/22/2025



## **Other Agenda Items**

### **Description:**

The Biosafety Officer will provide an update.

**Related Projects:** BIO20240038

**Notes:**

### **Description:**

January 21

February 18

March 18

April 15

May 20

June 17

July 15

August 19

September 16

October 21

November 18

December 16

**Related Projects:**

**Notes:**